Trial Profile
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary) ; Secukinumab (Primary)
- Indications Rheumatoid arthritis
- Focus Biomarker; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 10 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Oct 2013 Primary endpoint 'American-College-of-Rheumatology-20%-response-criteria' has been met.
- 28 Oct 2013 Primary endpoint 'Disease-activity-score' has been met.